Showing results (61-70 of 6,842) with videos related to
Sort By:
Pageof 685
Pharmacoeconomics|October 7, 2009
30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvementPeter J Neumann, Chi-Hui Fang, Joshua T CohenValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value FrameworksJoshua T Cohen, Jordan E Anderson, Peter J NeumannHealth Affairs (Project Hope)|September 13, 2006
Biotechnology and Medicare's new technology policy: lessons from three case studiesPatricia Seliger Keenan, Peter J Neumann, Kathryn A PhillipsClinical Orthopaedics and Related Research|January 24, 2007
Trends in cost effectiveness analyses in orthopaedic surgeryCarmen A Brauer, Peter J Neumann, Allison B RosenThe American Journal of Managed Care|December 21, 2019
Outcome measures for oncology alternative payment models: practical considerations and recommendationsJakub P Hlávka, Pei-Jung Lin, Peter J NeumannAmerican Journal of Public Health|October 17, 2008
Measuring the value of public health systems: the disconnect between health economists and public health practitionersPeter J Neumann, Peter D Jacobson, Jennifer A PalmerValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 28, 2024
Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness AnalysesFeng Xie, Ting Zhou, Brittany Humphries, et al.Journal of Managed Care & Specialty Pharmacy|October 31, 2019
Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care PharmacyLouis P Garrison, Peter J Neumann, Richard J WillkePharmacoeconomics|July 8, 2011
US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness researchPeter J Neumann, Pei-Jung Lin, Tom E HughesHealth Policy (Amsterdam, Netherlands)|December 16, 2014
Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)James D Chambers, Michael J Cangelosi, Peter J NeumannPageof 685